Evaluation of the effect of renal function test of beta & hbe/beta thalassaemia patients on trans-resveratrol threrapy

Resveratrol (3,5,4′-trihydroxystilbene), a natural polyphenolic compound found in grapes and red wine, is reported to have beneficial effects on cardiovascular diseases, including renal diseases. These beneficial effects are thought to be due to this compound's antioxidative properties: resveratrol is known to be a robust scavenger of reactive oxygen species (ROS). In addition to scavenging ROS, resveratrol may have numerous protective effects against age-related disorders, including renal diseases, through the activation of SIRT1. SIRT1, an NAD+-dependent deacetylase, was identified as one of the molecules through which calorie restriction extends the lifespan or delays age-related diseases, and this protein may regulate multiple cellular functions, including apoptosis, mitochondrial biogenesis, inflammation, glucose/lipid metabolism, autophagy, and adaptations to cellular stress, through the deacetylation of target proteins. This study we observed the pre-treatment and post-treatment of resveratrol and evaluation of blood CBC parameters in patients with beta and E-beta thalassaemia shows three categories of response: Complete Response (52.2%; in patients who can able to maintain at an average Hb level of 6-9 gm/dL without blood transfusion, in this group 12.3% patients are without any previous H/O blood transfusion, others shifted from monthly blood transfusion dependency to a stable transfusion-free condition); Partial Response (18.2%; in patients who remained transfusion dependent but at longer intervals : 2-3 months or more) and Non response (15.9%; in patients who, after more than one year of treatment, remained at the same level of transfusion dependency) and we observed the evaluation of RFT of Beta and Hb E/Beta thalassaemic patients on Trans Resveratrol Therapy.